GLPwatch

Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist.

J Control Release · 2020

Last updated 2026-05-28

Researchers developed an implantable pump that delivers the short-acting GLP-1 drug exenatide without needles or batteries. The pump releases a precise dose only when a magnetic force is applied externally, and it includes safety features to prevent accidental activation. In tests on rats, the pump performed as effectively as traditional injections, and its design allows for long-term use with minimal drug waste (~94% consumption).

AI summary of the abstract below.

JournalJ Control Release, 2020
Citations13
Relative citation ratio0.62
NIH percentile35
Molecules
Conditions studied Type 2 Diabetes, Obesity

Abstract

For type 2 diabetic patients, short acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) is often prescribed with frequent needled injections. Long-acting GLP-1 RA for less frequent injections do not mimic physiologic secretion of GLP-1. Therefore, an implantable pump is proposed in this work, which can deliver a short-acting GLP-1 RA, exenatide, without needles and batteries. The implanted pump can infuse an accurate amount of exenatide bolus only when a noninvasive magnetic force is applied from outside the body. The pump includes a safety feature of patterned magnets for actuation to prevent accidental infusion possibly caused by a general household magnet. The reservoir for exenatide is made of a flexible biomaterial and thus, a negative pressure build-up in the reservoir can be prevented even after multiple actuations and almost all drug consumption (~ 94%). This allows a reproducible drug dose for a longer period after implantation, hence less frequent replenishment procedures. The pump is also equipped with an intermediate container with two distinct check-valves and thus, the reservoir of exenatide can be further separated and better prevented from infiltration of the bodily fluid surrounding the implanted pump. When tested in Goto-Kakizaki rats, the pump demonstrates the efficacy of exenatide similar to conventional subcutaneous injections. Therefore, the pump can be promising for patient-friendly, optimal delivery of short-acting GLP-1 RA that better follows the physiologic secretion profile of GLP-1.

Verbatim abstract via PubMed 32619744 ↗